Your browser doesn't support javascript.
loading
Tissue Plasminogen Activator to Treat a Stroke after Foam Sclerotherapy in a Woman with a Patent Foramen Ovale.
Matsuzono, Kosuke; Arai, Naoto; Suzuki, Masayuki; Kim, Younhee; Ozawa, Tadashi; Mashiko, Takafumi; Shimazaki, Haruo; Koide, Reiji; Matsuura, Tohru; Fujimoto, Shigeru.
Afiliação
  • Matsuzono K; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan. Electronic address: kmatsuzono51@jichi.ac.jp.
  • Arai N; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Suzuki M; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Kim Y; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Ozawa T; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Mashiko T; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Shimazaki H; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Koide R; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Matsuura T; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Fujimoto S; Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
J Stroke Cerebrovasc Dis ; 27(6): e110-e112, 2018 Jun.
Article em En | MEDLINE | ID: mdl-29402614
ABSTRACT
Although foam sclerotherapy to varicose veins is now a popular treatment because of its high efficacy and safety, some neurologic complications have recently been reported. Presently, the effectiveness and safety of intravenous recombinant tissue-type plasminogen activator therapy to stroke following foam sclerotherapy remain unclear. Here, we report the case of a 68-year-old woman whose ischemic symptoms following foam sclerotherapy were treated by intravenous recombinant tissue-type plasminogen activator. After she was admitted, the venous thrombosis in her right soleus vein and a patent foramen ovale causing the right-to-left shunt were revealed. Thus, we diagnosed the ischemic symptoms were due to paradoxical embolism following foam sclerotherapy. After intravenous recombinant tissue-type plasminogen activator therapy, there was no complication and the outcome was good. Our case suggests the effectiveness and the safety of intravenous recombinant tissue-type plasminogen activator therapy to paradoxical embolism following foam sclerotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escleroterapia / Ativador de Plasminogênio Tecidual / Embolia Paradoxal / Acidente Vascular Cerebral / Forame Oval Patente / Fibrinolíticos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escleroterapia / Ativador de Plasminogênio Tecidual / Embolia Paradoxal / Acidente Vascular Cerebral / Forame Oval Patente / Fibrinolíticos Idioma: En Ano de publicação: 2018 Tipo de documento: Article